What doctors have to say about Trump’s announcement to reduce weight loss drug costs

Key Concepts

• GLP-1 Drugs: Glucagon-like peptide-1 receptor agonists, a class of medications primarily used for weight loss and managing type 2 diabetes.
• Most Favored Nation (MFN) Rate: A pricing agreement where a seller agrees to offer the lowest price to a particular buyer that they offer to any other buyer. In this context, it means drug companies will offer the lowest price to American patients that they offer to any other country.
• Obesity Epidemic: The widespread prevalence of obesity in the United States, with significant health and economic consequences.
• Medicare and Medicaid: Government health insurance programs for the elderly, disabled, and low-income individuals, respectively.
• Compounded Drugs: Medications created by combining, mixing, or altering ingredients to meet a specific patient's needs.
• Valvulopathy: Disease of the heart valves.
• Root Causes of Obesity: Underlying factors contributing to obesity beyond individual choices, such as food availability, processing, and socioeconomic determinants.

White House Announcement: Reduced Prices for Weight Loss Drugs

President Donald Trump announced a significant initiative at the White House aimed at reducing the cost of weight loss drugs, specifically GLP-1 agonists, for American patients. This initiative is a result of partnerships with major pharmaceutical companies Eli Lilly and Novo Nordisk.

Key Points and Figures:

• Price Reduction: The cost for eligible individuals could drop to just under $250 per month, a substantial decrease from the current average of around $1,500 per month (give or take a couple of hundred dollars).
• Targeted Drugs: The agreement specifically targets popular GLP-1 drugs like Zepbound (Eli Lilly) and Wegovy (Novo Nordisk).
• MFN Pricing: Eli Lilly and Novo Nordisk have committed to offering these drugs at "most favored nations rates" for American patients.
• Impact on Medicare and Medicaid: The agreement is expected to benefit 35 to 60 million beneficiaries of Medicare and Medicaid, who previously had limited or no access to these weight loss medications due to cost and existing regulations.
• Future Drug Launches: All future GLP-1 drug launches by Eli Lilly and Novo Nordisk will be sold at lower prices across Medicaid, Medicare, and commercial insurance, with widely used drugs potentially being 60% lower than current prices.
• Specific Price Examples:
  • Wegovy's lowest dose could drop from $1,350 per month to $250 per month.
  • Zepbound's lowest dose could start at $149 per month.
  • For Medicare patients, monthly out-of-pocket costs could drop from over $1,000 to as little as $50.

Expert Perspectives:

• Health and Human Services Secretary Robert F. Kennedy Jr.: Stated that this deal will have the "biggest impact on you at home, the American people" and is the "most important of all the MFN announcements." He emphasized that all Americans, even those not on Medicaid and Medicare, will be able to get the same price for their GLP drugs.
• Dr. Bio Curry Winell (Family Medicine Physician): Described the announcement as "instrumental for people to be able to access a drug that is... phenomenal." She noted that over 12% of Americans are currently accessing GLP drugs.
• Dr. Selene Gounder (CBS News Medical Contributor): Highlighted that the medications will not be available to "anybody who wants them who is on Medicare or Medicaid" and that being obese alone will not be an indication for reduced rates. Access is focused on individuals at high risk for complications of obesity, such as heart disease, stroke, and kidney failure. She also pointed out that while these drugs have shown other benefits like reduced risk of certain cancers and improved cognitive function, more data is needed for people who are overweight or obese but do not have other co-existing conditions.
• Dr. Holly Loftton (Director, NYU Langone Medical Weight Management Program): Emphasized that the price reduction can help 35 to 60 million Medicare and Medicaid beneficiaries gain access to these drugs for weight management and to improve other conditions like heart disease. She noted that in trials, diet and exercise alone typically lead to negligible weight loss (around 3%) without significant decreases in mortality or morbidity risk. She also explained that a 1990s law prevented CMS (Centers for Medicare & Medicaid Services) beneficiaries from covering weight loss drugs due to concerns about valvulopathy from older medications. However, GLP-1 agonists are now recognized as more than just appetite suppressants, impacting fat cells, brain-gut pathways, and reducing risks of heart disease, sleep apnea, and fatty liver.
• Dr. John Leuk (Reporter): Described the agreement as a "triumph for American patients that will save lives and improve the health of millions and millions of Americans." He noted that obesity is a crisis increasing the risk of various diseases and that many patients cannot afford GLP-1s. He also shared a quote from Dr. Memed: "obesity is not the absence of GLP drugs," underscoring the need to address root causes beyond medication.

Drug Development and Market Dynamics

Drug Development Process:

• Safety and Side Effects: Before a GLP-1 medication reaches the market, extensive testing is required to ensure its safety and identify potential side effects, allowing for appropriate responses.
• Time to Market: The process for a medication like a GLP-1 to come to market and be used by patients can take years.
• Late-Stage Trials: Eli Lilly has moved its obesity drugs to late-stage trials after showing promise, with mid-stage studies indicating patients lost as much as 20.1% of their weight.

Current Usage and Market Trends:

• Prevalence: A 2018 study indicated that over 8 million prescriptions for GLP-1s were used, averaging out to over 12% of Americans already using these drugs.
• Compounded Drugs: The emergence of compounded versions of weight loss drugs was largely a response to shortages of name-brand medications. However, once the FDA declared shortages over, these compounded versions became illegal. Companies like Novo Nordisk and Eli Lilly are now pursuing legal action against compounding pharmacies for replicating their patented drugs, citing issues with safety, efficacy, and patent infringement.

Broader Health Implications and Future Outlook

Obesity as a Public Health Crisis:

• Obesity affects at least 40% of the American population, with significant implications for chronic diseases.
• These GLP-1 drugs are seen as a crucial part of a multi-faceted solution to the obesity epidemic, but not a "silver bullet" on their own.

Beyond Weight Loss: Other Health Benefits:

• GLP-1 drugs have demonstrated benefits beyond weight management, including:
  • Reduced risk of certain cancers.
  • Improved cognitive function.
  • Decreased risk of heart disease.
  • Reduced risk of sleep apnea.
  • Treatment of fatty liver disease.
• The long-term impact of these drugs on preventing conditions like cancer and cognitive decline in a broader population is still under investigation.

Addressing Root Causes:

• There is a consensus among public health experts that addressing the "root causes" of obesity is essential. This includes:
  • Diet and exercise.
  • Improved availability of fresh, affordable food free of ultra-processing.
  • A deeper dive into other contributing factors that may not be immediately obvious.

Conclusion

The White House announcement signifies a major step towards making GLP-1 weight loss drugs more accessible and affordable for a significant portion of the American population, particularly those on Medicare and Medicaid. While these drugs offer substantial benefits for weight management and reducing the risk of various chronic diseases, experts emphasize that they are part of a larger strategy that must also address the underlying societal and environmental factors contributing to the obesity epidemic. The legal challenges surrounding compounded drugs also highlight the importance of regulated and approved medications for patient safety and efficacy.